Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome

PHASE3CompletedINTERVENTIONAL
Enrollment

436

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Cutaneous Malignant Melanoma
Interventions
DRUG

Vitamin D

"* prospective interventional randomized double blind placebo controlled trail~* clinical setting (tertiary university hospital)~* investigator driven, no pharmaceutical sponsor~* cutaneous malignant melanoma patients~* add- on study (placebo or vitamin D) on top of optimal standard care~* 1:1 inclusion ratio (placebo:Vitamin D)~* randomisation after informed consent and screening"

DRUG

Placebo: Oil

Trial Locations (4)

2650

Universitair Ziekenhuis Antwerpen, Dermatology, Edegem

3000

UZLeuven Gasthuisberg, Leuven

4000

Chef de Service du Service Universitaire de Dermatologie, Liège

4032

Dep. of Dermatology, Medical and Health Science Center University of Debrecen, Debrecen

All Listed Sponsors
collaborator

KU Leuven

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT01748448 - Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome | Biotech Hunter | Biotech Hunter